Magnera reported fourth quarter 2026 revenue of $851 million, a 1% increase year-over-year, as higher selling prices offset a 4% decline in organic volumes. The company recognized a GAAP operating loss of $90 million for the quarter, primarily driven by $106 million in non-cash impairment charges, while achieving record quarterly operating cash flow of $99 million.
Key Highlights
- Adjusted EBITDA rose 8% to $97 million in the fourth quarter, supported by a $9 million favorable price-cost spread and Project CORE synergies.
- Organic volume declined 4% during the period, which management attributed to soft healthcare demand in the Americas and broader market weakness in Europe.
- Fiscal year 2026 free cash flow reached $115 million, enabling $122 million in total debt repayments for the full year.
- Guidance for fiscal year 2027 projects Adjusted EBITDA between $390 million and $410 million, implying approximately 6% growth at the midpoint.